Related references
Note: Only part of the references are listed.Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
Kikushima Wataru et al.
PLOS ONE (2020)
Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
Seigo Yoneyama et al.
SCIENTIFIC REPORTS (2020)
Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration
Taiyo Shijo et al.
INTERNATIONAL OPHTHALMOLOGY (2020)
Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
Simon Javidi et al.
JOURNAL OF OPHTHALMOLOGY (2020)
Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration
Taiyo Shijo et al.
PHARMACEUTICALS (2020)
Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
Arshad M. Khanani et al.
CLINICAL OPHTHALMOLOGY (2019)
Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline
Sakiko Minami et al.
SCIENTIFIC REPORTS (2018)
Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
Wataru Kikushima et al.
SCIENTIFIC REPORTS (2017)
Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
Wataru Kikushima et al.
SCIENTIFIC REPORTS (2017)
Factors Predictive of Visual Outcome 1 Year After Intravitreal Aflibercept Injection for Typical Neovascular Age-Related Macular Degeneration
Wataru Kikushima et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2016)
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration The Comparison of Age-Related Macular Degeneration Treatments Trials
Maureen G. Maguire et al.
OPHTHALMOLOGY (2016)
ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Treat-and-Extend Protocol Over 2 Years
Farshad Abedi et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Prevalence of Age-Related Macular Degeneration in Asians A Systematic Review and Meta-Analysis
Ryo Kawasaki et al.
OPHTHALMOLOGY (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
